Q-omics provides the consensus-scored SNHG10 profile across patient tissues and cancer cell-line models. SNHG10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNHG10 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SNHG10 RNA expression shows 21,756 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where SNHG10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG10 survival associations across molecular data types. SNHG10 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG10 RNA expression–survival associations across cancer types. High SNHG10 expression shows unfavorable associations in ACC, KIRC, PRAD and UVM, but favorable associations in PAAD and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNHG10 RNA expression.
This table summarizes SNHG10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG10 shows lower tumor expression in KICH and KIRC and higher tumor expression in BLCA, COAD, LIHC and HNSC. The BLCA box plot shows higher SNHG10 RNA expression in tumor versus normal tissue (log2 FC = +1.344, t-test p < 0.001).
This table shows molecular features associated with SNHG10 in patient tissues and cancer cell lines. In patient samples, SNHG10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
